Thyroid Cancer Molecular Signaling Pathways and Use of Targeted Therapy

Endocrinology and Metabolism Clinics of North America

Volumn 36, Issue 3, 2007, Pages 839-853

  Kundra, Priya ^a   Burman, Kenneth D ^a,b  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AXITINIB; BORTEZOMIB; CAPECITABINE; COMBRETASTATIN A4; DACARBAZINE; FR 901228; IMATINIB; IRINOTECAN; LENALIDOMIDE; PROTEIN TYROSINE KINASE INHIBITOR; ROSIGLITAZONE; SORAFENIB; SUNITINIB; VANDETANIB;

CANCER THERAPY; DRUG INHIBITION; DRUG MECHANISM; HUMAN; PRIORITY JOURNAL; REVIEW; THYROID CANCER; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA;

ANGIOGENESIS INHIBITORS; APOPTOSIS; ENZYME INHIBITORS; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; HISTONE DEACETYLASES; HSP90 HEAT-SHOCK PROTEINS; HUMANS; PPAR GAMMA; PROTEIN-TYROSINE KINASES; RAS PROTEINS; SIGNAL TRANSDUCTION; THYROID NEOPLASMS;

EID: 34547236124     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2007.06.001     Document Type: Review

References (51)

1. American Cancer Society Web site 2005.
2. Zhu Z., Gandhi M., Nikiforova M.N., et al. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol 120 (2003) 71-77
3. Xing M. BRAF mutations in thyroid cancer. Endocr Relat Cancer 12 (2005) 245-62
4. Kondo T., Ezzat S., and Asa S.L. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6 (2006) 292-306
5. Sarlis N.J., and Gourgiotis L. Molecular elements of apoptosis-regulating pathways in follicular thyroid cells: mining for novel therapeutic targets in the treatment of thyroid carcinoma. Curr Drug Targets Immune Endocr Metabol Disord 4 (2004) 187-198
6. Yeung S.C., Xu G., Pan J., et al. Manumycin enhances the cytotoxic effect of paclitaxel on anaplastic thyroid carcinoma cells. Cancer Res 60 (2000) 650-656
7. Xu G., Pan J., Martin C., et al. Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma. J Clin Endocrinol Metab 86 (2001) 1769-1777
8. Carlomagno F., Anaganti S., Guida T., et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 98 5 (2006) 326-334
9. Tuttle R.M., Fleisher M., Francis G.L., et al. Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation. J Clin Endocrinol Metab 87 4 (2002) 1737-1742
10. Ye C., Feng C., Wang S., et al. SFLT-1 gene therapy of follicular thyroid carcinoma. Endocrinology 145 (2004) 817-822
11. Bauer A.J., Aptel A., Terrell R., et al. Systemic administration of vascular endothelial growth factor monoclonal antibody reduces the growth of papillary thyroid carcinoma in a nude mouse model. Ann Clin Lab Sci 33 (2003) 192-199
12. Hung C.J., Zarnegar R., Ginzinger D.G., et al. Expression of vascular endothelial growth factor-C in benign and malignant thyroid tumors. J Clin Endocrinol Metab 88 (2003) 3694-3699
13. Bauer A., Terrell R., Doniparthi K., et al. Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice. Thyroidology 12 (2002) 953-961
14. Schiff B., McMurphy A.B., Jasser S.A., et al. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor Gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res 10 (2004) 8594-8602
15. Nobura Y., Onoda N., Yamashita Y., et al. Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines. Br J Cancer 92 (2005) 1110-1116
16. Carlomagno F., Vitagliano D., Guida, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 62 (2002) 7284-7290
17. Kim D., Jo Y.S., Jung H.S., et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 91 10 (2006) 4070-4076
18. Kim S., Schiff B.A., and Yigitbasi O.G. Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788. Mol Cancer Ther 4 4 (2005) 632-640
19. Schoenberger J., Grimm D., Kossmehl P., et al. Effects of PTK787/ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: an animal study. Endocrinology 145 3 (2004) 1031-1038
20. Cuccuru G., Lanzi C., Cassinelli G., et al. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma. J Natl Cancer Inst 96 13 (2004) 1006-1014
21. Kundra P, Burman K. Molecular pathogenesis of endocrine cancers. In: Molecular basis of cancer. 3rd edition. in press.
22. Carniti C., Perego C., Mondellini P., et al. PP1 inhibitor induces degradation of RETMEN2A and RETMEN2B oncoproteins through proteosomal targeting. Cancer Res 63 (2003) 2234-2243
23. Carlomagno F., Vitagliano D., Guida T., et al. Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phemyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). J Clin Endocrinol Metab 88 4 (2003) 1897-1902
24. Strock C., Park J.I., Rosen M., et al. CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth. Cancer Res 63 (2003) 5559-5563
25. Podtcheko A., Ohtsuru A., Tsuda S., et al. The selective tyrosine kinase inhibitor, ST1571, inhibits growth of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 88 4 (2003) 1889-1896
26. Dziba J., and Ain K. Imatinib mesylate (Gleevec; ST1571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro. J Clin Endocrinol Metab 89 5 (2004) 2127-2135
27. Dowlati, Robertson K., Cooney M., et al. A phase I pharmokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62 (2002) 3408-3416
28. Dziba J., Marcinek R., Venkataraman G., et al. Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors. Thyroidology 12 12 (2002) 1063-1070
29. Ain K., Lee C., Williams K., et al. Phase II trial of thalidomide for therapy of radioiodine-unresponsive papillary and follicular thyroid carcinomas and medullary thyroid carcinomas: preliminary results. [abstract]. Cancer Invest 21 suppl 1 (2002) 38
30. Straight A., Oakley K., Moores R., et al. Aplidin reduces the growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes. Cancer Chemother Pharmacol 57 (2006) 7-14
31. Mandal M., Younes M., Swan E.A., et al. The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells. Br J Cancer 92 (2005) 1899-1905
32. Younes M., Kim S., Yigitbasi O.G., et al. Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer. Mol Cancer Ther 4 8 (2005) 1146-1156
33. Mrozek, Kloos R.T., Ringel M.D., et al. Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. J Clin Endocrinol Metab 91 6 (2006) 2201-2204
34. Smit J., van Tol K.M., Hew J.M., et al. Marimastat therapy as adjuvant to selective embolization in skeletal metastases of differentiated thyroid carcinoma. Clin Endocrinol 55 (2001) 421-422
35. Braga-Basaria M., Hardy E., Gotfried R., et al. 17-Allylamino-17-demethoxygeldanamycin activity against thyroid cancer cell lines correlates with heat shock protein 90 levels. J Clin Endocrinol Metab 89 6 (2004) 2982-2988
36. Marsee D., Venkateswaran A., Tao H., et al. Inhibition of heat shock protein 90, a novel RET/PTC1-associated protein, increases radioiodide accumulation in thyroid cells. J Biol chem 279 42 (2004) 43990-43997
37. Elisei R., Vivaldi A., Ciampi R., et al. Treatment with drugs able to reduce iodine efflux significantly increases the intracellular retention time in thyroid cancer cells stably transfected with sodium iodide symporter complementary deoxyribonucleic acid. J Clin Endocrinol Metab 91 6 (2006) 2389-2395
38. Kitazono M., Robey R., Zhan Z., et al. Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na+/I- symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab 86 7 (2001) 3430-3435
39. Mitsiades C.S., Poulaki V., and McMullan C. Novel histone deacetylase inhibitors in the treatment of thyroid cancer. Clin Cancer Res 11 10 (2005) 3958-3965
40. Kelly W., O'Connor O.A., Heaney M.L., et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23 (2005) 3923-3931
41. Venkataraman G., Yatin M., Marcinek R., et al. Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I- symporter gene methylation status. J Clin Endocrinol Metab 84 (1999) 2449-2457
42. Strock J., Park J.I., Rosen D.M., et al. Activity of Irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer. J Clin Endocrinol Metab 91 1 (2006) 79-84
43. Kim S., Prichard C.N., Younes M.N., et al. Cetuximab and Irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Clin Cancer Res 12 2 (2006) 600-607
44. Ohta K., Endo T., Haraguchi K., et al. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 86 (2001) 2170-2177
45. Martelli M., Iuliano R., Le Pera I., et al. Inhibitory effects of peroxisome proliferator-activated receptor gamma on thyroid carcinoma cell growth. J Clin Endocrinol Metab 87 (2002) 4728-4735
46. Jiang S., Altmann A., Grimm D., et al. Tissue-specific gene expression in medullary thyroid carcinoma cells employing calcitonin regulatory elements and AAV vectors. Cancer Gene Ther 8 (2001) 469-472
47. Barzon, Pacenti M., Taccaliti A., et al. A pilot study of combined suicide/cytokine gene therapy in two patients with end-stage anaplastic thyroid carcinoma. J Clin Endocrinol Metab 90 (2005) 2381-2384
48. Nagayama Y., Yoloi H., Takeda K., et al. Adenovirus-mediated tumor suppressor p53 gene therapy for anaplastic thyroid carcinoma in vitro and in vivo. J Clin Endocrinol Metab 85 (2000) 4081-4086
49. Juweid M., Sharkey R.M., Behr T., et al. Radioimmunotherapy of medullary thyroid cancer with iodine-I131-labeled anti-CEA antibodies. J Nucl Med 37 (1996) 905-911
50. Bachleitner-Hofmann T., Stift A., Friedl J., et al. Stimulation of autologous antitumor T-cell responses against medullary thyroid carcinoma using tumor lysate-pulsed dendritic cells. J Clin Endocrinol Metab 87 (2002) 1098-1104
51. Schott M., Seissler J., Lettmann M., et al. Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination. J Clin Endocrinol Metab 86 (2001) 4965-4969